Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and ADC for Patients with Previously Treated HER2+ ...

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Commission (EC) has approved their ...

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial ...

The DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology annual meeting, established ...

Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...

Brain metastases are a major challenge in HER2-positive metastatic breast cancer; epidemiologic series suggest that roughly 30%–50% of patients eventually develop brain involvement, which is ...

What Is It, and Why Does It Matter? Enhertu (fam-trastuzumab deruxtecan-nxki) is a type of targeted cancer treatment called an antibody-drug conjugate. The FDA has approved it in combination with ...

Incidence high in HR-negative patients, but there are effective therapies ...

The MUHC is the first site in the world to launch a first-in-human Phase I clinical trial evaluating a novel radioligand ...

Priority Review and Real-Time Oncology Review aim to accelerate regulatory assessment of zanidatamab-based first-line regimens for HER2-positive advanced gastroesophageal adenocarcinoma, with an ...

Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase ...